Pancreatic cancer remains a deadly disease with limited treatment options. The current standards of treatment are mFOLFIRINOX and gemcitabine + Abraxane. Market growth over the forecast period to 2020 will be driven by the premium-priced products Abraxane and Onivyde and then, over the five years to 2025, by the new product introductions of Lynparza and PEGPH20. Longer-term promise lies in emerging dual and multiple combinations of targeted agents, particularly the PD-1 and PD-L1 checkpoint inhibitors.


Related Reports

Pancreatic Cancer | Epidemiology | Epidemiology Dashboard

DRG Epidemiology’s coverage of pancreatic cancer comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevale...

View Details

Pancreatic Cancer | Landscape & Forecast | Disease Landscape & Forecast

Pancreatic cancer is a notoriously aggressive and hard-to-treat malignancy; the five-year survival rate is less than 10%. Treatment options for pancreatic cancer are limited to surgery, radiation...

View Details

Pancreatic Cancer | Epidemiology | Extrapolated Worldwide Coverage

DRG’s extended worldwide coverage is the first and only evidence-based data set of epidemiological forecasts for key  pancreatic cancer&nb...

View Details

Pancreatic Cancer | Unmet Need | Detailed, Expanded Analysis (US/EU) Locally Advanced or Metastatic Adenocarcinoma

MARKET OUTLOOK Pancreatic cancer is a life-threatening disease with a survival rate of less than 10% and with no improvements in the last 40 years. Owing to the lack of...

View Details